<DOC>
	<DOCNO>NCT02658825</DOCNO>
	<brief_summary>The purpose study evaluate effect JNJ-63623872 QT/QTc interval supratherapeutic exposure healthy participant ( Panel 2 ) .</brief_summary>
	<brief_title>A Study Evaluate Effect JNJ-63623872 Cardiac Repolarization Interval Healthy Participants</brief_title>
	<detailed_description>This two-part Phase 1 study consist dose escalation part ( Panel 1 ) thorough QT ( TQT ) part ( Panel 2 ) . Panel 1 double-blind ( neither researcher participant know treatment participant receiving ) , randomize ( study medication assign participant chance ) , placebo-controlled dose escalation study healthy participant determine safety , tolerability pharmacokinetics JNJ-63623872 administration single dos 2400 milligram ( mg ) 3000 mg fast condition . The final dose use Panel 2 determine base result dose escalation part . An interim analysis conduct Panel 1 select dose Panel 2 . Panel 2 double-blind , double-dummy , randomize , 3-period crossover ( medication provide participant different sequence ) , placebo- positive control study evaluate effect JNJ-63623872 QT/QTc interval healthy participant . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Each participant must sign Informed consent form ( ICF ) indicate understands purpose procedure require study willing participate study Participant must willing able adhere prohibition restriction specify protocol A female participant must agree donate egg ( ovum , oocytes ) study least 90 day receive ( last dose ) study drug A male participant sexually active woman childbearing potential must agree use two effective method contraception study least 90 day receive ( last dose ) study drug , male participant must also donate sperm study least 90 day receive ( last dose ) study drug Participants must nonsmoker least 3 month prior Screening Participants must Body Mass Index ( BMI ) 18.0 30.0 kilogram per meter^2 ( kg/m^2 ) ( inclusive ) Screening Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result Participants history clinically relevant heart rhythm disturbance include atrial , junctional , reentry , ventricular tachycardia , heart block Participants unusual T wave morphology ( bifid T wave ) likely interfere QTc measurement Participants electrolyte abnormality ( hypokalemia , hypocalcemia , hypomagnesemia ) grade 2 within 21 day prior ( first ) intake study drug Participants breast implant history thoracic surgery likely cause abnormality electrical conduction thoracic tissue Participant take disallowed therapy ( Concomitant Therapy ) plan ( first ) intake study drug Participant know allergy , hypersensitivity , intolerance JNJ63623872 , moxifloxacin excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-63623872</keyword>
	<keyword>Moxifloxacin</keyword>
</DOC>